Isodiol International Inc (OTCMKTS: ISOLF) Primed To Bottom Out

Isodiol International Inc (OTCMKTS: ISOLF) has seen its share price dwindle since the start of the year. The stock has been trading in a range after coming under pressure over the past 12 months.Isodiol International Price AnalysisA plunge to all-time lows leaves the stock in dire need of new catalysts to avert further slides. The confirmation that the Company remains confident about CBD opportunities in Mexico is one of the developments that continue to prop the stock’s market sentiments.Mexico is in the process of legalizing CBD expected to create new opportunities that Isodiol International remains focused on. In addition to expanding into Mexico, Isodiol International has also expanded its product line with the unveiling of an all-natural CBD supplement line targeting sales opportunities in the Pet industry.In April, the Company strengthened its balance sheet with the sale of its wholly owned subsidiary BSPG Laboratories for $14 million. The sale provided the Company the much-needed cash to oversee the core business into 2020.The stock has however struggled for direction in the market, having traded sideways in a tight trading range of between $1.50 and $0.79 for the better pay of the year. A sell-off followed by a close below the $0.79 mark could result in the stock plunging further in continuation of the long term descending trend line. ISOLF Daily ChartConversely, Isodiol needs to rally and take out the $1.50 resistance level, to have a chance of bottoming out of all-time lows. Above the $1.50 mark, the stock stands a better chance of making a run for the $2.40 resistance level.What Does Isodiol International Do?Isodiol International is engaged in the development, marketing and distribution of hemp-based consumer products in North America, Europe, Asia as well as Latin America. The Company develops and manufactures phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds.[embed]https://www.youtube.com/watch?v=xBK9-mrBnS0&t=7s[/embed]European Sales OpportunityAmidst the underperformance in the stock market, Isodiol International has continued to make strategic moves that position it for long-term growth. European expansion has already come into play as the Company seeks to diversify its streams of revenues.A deal with Holland & Barrett International has seen the Company ink a deal, for ten SKUs of Hemp extract based cannabidiol products. The deal is worth more than $1 million. It will result in the sale of the RapidCBD and Is-Sport brand, throughout the United Kingdom and Ireland.

“Gaining a foothold in the European market and getting Isodiol products on the shelves of such a respected retailer is a significant milestone in the Company’s development. Although the U.K. and E.U. markets are highly regulated, the opportunities to provide Isodiol pioneering hemp-based consumer packaged goods (CPG) to a new and growing CBD market outweigh those challenges,” stated Business Development VP Graham Boylan.

Strengthened Balance SheetThe sale of the BSPG laboratories Ltd for $14 million provides Isodiol with the much-needed finances for meeting supply needs. The Company remains well financed to fulfill its Purodiol, and Isodiol production needs to cater to the growing demand in Europe and in North America. The Company should also be able to finance all its clinical research projects at below market costs.In addition, Isodiol has commenced its cannabidiol vending machine program with an initial launch of Is-Sport products in Powerhouse Germ locations across the U.S.

“As we continue our focus on the Consumer Packaged Goods (CPG) market, the additional awareness and retail opportunities that our vending machine program with Powerhouse brings to Is-Sport™ is very promising, and we look forward to numerous expansion opportunities,” stated CEO Marcos Garamond.

Isodiol is also keenly following developments in Mexico in relations to the legalization of cannabis products. The Company established operations in the country in 2017. As soon as the regulatory environment becomes clear, the Company intends to apply its medical product license applications as part of an effort of strengthening its CBD product sales channel.What Next For Isodiol InternationalThere is no doubt that Isodiol International has underperformed the industry for the better part of the year. While the underperformance is a point of concern, the Company’s long-term prospects and growth metrics remain intact.Expansion into Europe, as well as the pursuit of opportunities in Mexico, affirm the Company’s tremendous potential going forward. That said the share price does not reflect the Company's immense potential. We believe the lows are in for ISOLF and better days are ahead.We will be updating our subscribers as soon as we know more. For the latest updates on ISOLF, sign up below!Disclosure: We have no position in ISOLF and have not been compensated for this article.